This research aimed to identify reporting patterns related to suboptimal therapeutic outcomes and tirzepatide-related drug-use issues by analyzing data from the EudraVigilance (EV) database. The study utilized descriptive and disproportionality analyses of individual case safety reports involving tirzepatide, comparing them with other GLP-1 receptor agonists (RAs) within the overall dataset and specifically within healthcare professional (HP) reports.
Key Clinical Findings
The analysis encompassed reports from both healthcare professionals and non-healthcare professionals. Key outcome measures involved reporting odds ratios (RORs) with 95% confidence intervals (CIs) for selected Preferred Terms (PTs) related to drug-use issues. Frequently reported PTs included ‘Off-label use’ (n=1521), ‘Drug ineffective’ (n=425), and ‘Off-label use device’ (n=99).
Within the overall dataset, reports involving tirzepatide demonstrated lower reporting odds for the PT ‘Drug ineffective’ compared to reports involving liraglutide (ROR 0.61, 95% CI 0.54 to 0.70), dulaglutide (ROR 0.72, 95% CI 0.63 to 0.82), exenatide (ROR 0.78, 95% CI 0.67 to 0.92) and semaglutide (ROR 0.81, 95% CI 0.72 to 0.91). However, in HP reports, no difference in reporting odds was observed between tirzepatide and semaglutide regarding this PT. A different pattern was observed for ‘off-label use’ in the full dataset, with higher reporting odds for tirzepatide compared to lixisenatide, dulaglutide and liraglutide, but lower reporting odds compared to semaglutide (ROR 0.52, 95% CI 0.49 to 0.55). Furthermore, a higher reporting odd for the PT ‘off-label use of device’ was observed for tirzepatide versus semaglutide (ROR 43.47, 95% CI 16.00 to 118.13) in the overall reports; however, this finding should be interpreted with caution given the wide confidence interval. This study complements existing evidence from clinical trials and current clinical practice.